17:10:33 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-29 Kvartalsrapport 2024-Q1
2024-05-27 X-dag ordinarie utdelning SANION 0.00 SEK
2024-05-25 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2024-01-16 Extra Bolagsstämma 2024
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-25 Årsstämma 2023
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-24 X-dag ordinarie utdelning SANION 0.00 SEK
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-08-18 Extra Bolagsstämma 2022
2022-05-27 X-dag ordinarie utdelning SANION 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-25 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-09-16 Extra Bolagsstämma 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-27 X-dag ordinarie utdelning SANION 0.00 SEK
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-26 Årsstämma 2021
2021-03-17 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3
2020-10-23 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-28 X-dag ordinarie utdelning SANION 0.00 SEK
2020-05-06 Kvartalsrapport 2020-Q1
2020-05-06 Årsstämma 2020
2020-02-07 Extra Bolagsstämma 2019
2020-02-07 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 X-dag ordinarie utdelning SANION 0.00 SEK
2019-05-29 Kvartalsrapport 2019-Q1
2019-05-29 Årsstämma 2019
2019-02-21 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-25 X-dag ordinarie utdelning SANION 0.00 SEK
2018-05-24 Kvartalsrapport 2018-Q1
2018-05-24 Årsstämma 2018
2018-02-21 Bokslutskommuniké 2017
2018-01-19 Extra Bolagsstämma 2018
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-24 X-dag ordinarie utdelning SANION 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-11 Kvartalsrapport 2017-Q1
2017-02-21 Bokslutskommuniké 2016
2016-10-13 Extra Bolagsstämma 2016
2016-05-11 X-dag ordinarie utdelning SANION 0.00 SEK
2016-05-10 Årsstämma 2016
2016-05-10 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-20 Kvartalsrapport 2015-Q3
2015-09-04 Extra Bolagsstämma 2015
2015-08-31 Kvartalsrapport 2015-Q2
2015-05-21 X-dag ordinarie utdelning SANION 0.00 SEK
2015-05-20 Kvartalsrapport 2015-Q1
2015-05-20 Årsstämma 2015
2015-02-20 Bokslutskommuniké 2014
2014-11-21 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2


ListaSmall Cap Stockholm
Saniona är verksamt inom bioteknik. Idag bedrivs forskning och utveckling av läkemedel för behandling av nervsjukdomar samt övriga autoimmuna sjukdomar. Läkemedelsportföljen är bred och innefattar läkemedel som för närvarande befinner sig i olika kliniska faser. En del av arbetet utförs även i samarbete med andra aktörer inom läkemedelsbranschen. Saniona har huvudkontor i Glostrup.
2023-11-30 08:00:00
Three Months Ended September 30, 2023 (2022)Nine Months Ended September 30, 2023 (2022)
Revenue was SEK 5.5 M (2.4 M)Revenue was SEK 11.5 M (12.0 M)
Operating profit/loss was SEK -18.4 M (21.8 M)Operating profit/loss was SEK -61.3 M (-203.1 M)
Net profit/loss was SEK -24.1 M (17.5 M)Net profit/loss was SEK -67.1 M (-204.4 M)
Basic earnings/loss per share was SEK -0.38 (0.28)Basic earnings/loss per share was SEK -1.05 (-3.28)
Diluted earnings/loss per share were SEK -0.38 (0.28)Diluted earnings/loss per share were SEK -1.05 (-3.28)

Business highlights in Q3 2023

  • In July, Saniona announced a new collaboration agreement with AstronauTx in Alzheimer’s disease. Saniona may receive up to SEK 1.9 billion ($177 million) in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration.
  • In August, Saniona announced a change to the terms of the loan agreement with Formue Nord. The parties agreed to reduce the loan value, through a repayment of SEK 3 million by Saniona and a conversion of SEK 10 million into shares at 8.50 SEK per share. Formue Nord has also received a commitment fee of SEK 4.8 million, which also was converted into shares at 8.50 SEK per share. The maturity date of the loan agreement changed to January 31, 2025.

Significant events after the reporting period

  • In October, Saniona’s new partner, AstronauTx, closed a $61 million Series A financing led by the Novartis Venture Fund and backed by several other leading global venture investors, including Brandon Capital, Bristol Myers Squibb, EQT Life Sciences investing from the LSP Dementia Fund, MPM Capital and the Dementia Discovery Fund.
  • Professor Vincenzo Crunelli, Cardiff University, U.K., presented preclinical data on Saniona’s lead ion-channel drug candidate and phase 2 ready asset, SAN711, at the annual meeting of the Society for Neuroscience (SfN) 11th-15th November 2023, Washington DC. The data shows strong suppression of absence seizures, which demonstrates that SAN711 represents a novel precision approach for treatment of non-convulsive generalized seizures.
  • In November, Saniona announced that it has initiated the candidate selection phase with a proprietary subtype selective frontrunner molecule from Kv7 lead optimization program for epilepsy.

Comments from the CEO
““We have a broad pipeline, which we develop in collaboration with partners. We have a long and successful history of finding and negotiating partnerships, such as the new collaboration with AstronauTx in Alzheimer’s disease. Based on our business discussions, I am confident that we will reach additional partnerships. In parallel we are leveraging our expertise in ion-channel drug discovery to identify and advance additional clinical candidates in a range of epilepsy indications. Saniona has a lot to offer in epilepsy and may create significant value for the shareholders in this field.”